Vistagen Therapeutics (VTGN) Operating Expenses (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Operating Expenses of $17.2 million for Q1 2026, down 13.44% sequentially from $19.8 million in Q4 2025, and up 18.66% YoY from $14.5 million in Q1 2025.
Vistagen Therapeutics (VTGN) Operating Expenses (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Operating Expenses for 16 years, with the latest figure at $17.2 million in Q1 2026.
- Quarterly Operating Expenses rose 18.66% year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.4 million (up 29.99% YoY) and the FY2026 annual result came in at $73.4 million, up 30.0% from the prior year.
- Operating Expenses eased to $17.2 million in Q1 2026 per VTGN's latest filing, from $19.8 million in the prior quarter.
- Over five years, Operating Expenses peaked at $20.3 million in Q3 2025 and troughed at $7.1 million in Q3 2023.
- A 5-year average of $14.1 million and a median of $14.5 million in 2025 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses soared 151.19% in 2022, then sank 64.27% in 2023.
- Over 5 years, Operating Expenses stood at $9.9 million in 2022, then fell by 16.6% to $8.3 million in 2023, then soared by 85.1% to $15.4 million in 2024, then gained by 29.28% to $19.8 million in 2025, then retreated by 13.44% to $17.2 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $17.2 million, $19.8 million, and $20.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | 14.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.18 Mn |
| Dec 31, 2025 | 19.85 Mn |
| Sep 30, 2025 | 20.31 Mn |
| Jun 30, 2025 | 16.05 Mn |
| Mar 31, 2025 | 14.48 Mn |
| Dec 31, 2024 | 15.35 Mn |
| Sep 30, 2024 | 14.41 Mn |
| Jun 30, 2024 | 12.22 Mn |
| Mar 31, 2024 | 11.56 Mn |
| Dec 31, 2023 | 8.30 Mn |
| Sep 30, 2023 | 7.06 Mn |
| Jun 30, 2023 | 7.18 Mn |
| Mar 31, 2023 | 12.42 Mn |
| Dec 31, 2022 | 9.95 Mn |
| Sep 30, 2022 | 16.60 Mn |
| Jun 30, 2022 | 20.08 Mn |
| Mar 31, 2022 | 16.73 Mn |
| Dec 31, 2021 | 10.90 Mn |
| Sep 30, 2021 | 13.16 Mn |
| Jun 30, 2021 | 8.10 Mn |